Volume 9, Number 11—November 2003
Synopsis
Toxoplasma gondii and Schizophrenia
Table
Y | Author and country | Test used | Patients | Controls | % Patients antibody positive | % Controls antibody positive | p value chi square | |
---|---|---|---|---|---|---|---|---|
Before 1980 | ||||||||
1953 | Kozar (15) Poland | Skin test | Psychiatric inpatients, all diagnoses | Healthy persons, ages 18–60 | 52 (495/961) | 25 (170/681) | <0.0001 | |
1956 | Vojtechovská et al. (16) Czechoslovakia | Skin test | Inpatients with “psychosis” | General population | 59 (68/116) | 30 (not specified) | <0.0001 | |
1956 | Wende (17) East Germany | Dye test | Inpatients with schizophrenia | Inpatients with neurologic disorders | 8 (3/38) | 5 (24/520) | 0.418 | |
1957 | Jirovec et al. (18) Czechoslovakia | Skin test | Inpatients with schizophrenia | Normal population | 48 (238/501) | 29 (286/970) | <0.0001 | |
1958 | Buentello (19) Mexico | Color change in fish | Inpatients with schizophrenia | Normal subjects | 69 (29/42) | 0 (0/60) | <0.0001 | |
1958 | Caglieris (20) Italy | Dye test | Inpatients with schizophrenia | Normal subjects | 21 (13/61) | 15 (12/81) | 0.376 | |
1961 | Cook & Derrick (21) Australia | Dye test C.F. | Inpatients with schizophrenia | General population | 36 (19/53) ≥1:16 11 (6/53) ≥1:4 | 24 (182/760) 13 (99/760) | 0.053 0.840 | |
1962 | Yegerov et al. (22) Russia | Skin test C.F. | Inpatients with schizophrenia | Hospital employees | 19 (7/37) 32 (12/37) | 4 (1/25) 28 (7/25) | 0.124 0.784 | |
1962 | Avlavidov (23) Bulgaria | Skin test C.F. | Psychiatric inpatients, not specified | Female surgical patients | 26 (5/19) 21 (3/14) | 3 (1/35) 9 (3/34) | 0.017 0.339 | |
1966 | Berengo et al. (24) Italy | Dye test | Inpatients with schizophrenia | General population | 14 (76/560) | 4% (49/1200) | <0.0001 | |
1966 | Roch & Varela (25) Mexico | Dye test | Schizophrenia, hospital status not specified | General population | 86% (836/973) | 30% (4,411/14,689) | <0.0001 | |
1968 | Garrido & Redondo (26) Spain | C.F. | Inpatients with schizophrenia | General population | 44 (17/39) | 29 (147/500) | 0.072 | |
1979 | Garcia (27) Cuba | Skin test | Psychiatric inpatients | Normal persons | 60 (60/100) | 30 (30/100) | <0.0001 | |
Since 1999 | ||||||||
1999 | Qiuying et al. (28) China | EIA | Inpatients with schizophrenia | Normal persons from same region for routine physicals | 14 (22/152) | 10 (41/396) | 0.181 | |
2001 | Gu et al. (29) China | EIA | First-episode schizophrenia | Normal controls matched for age, sex, birthplace | 33 (45/135) | 9 (4/43) | 0.002 | |
2001 | Yolken et al. (30) Germany | EIA: IgG or IgM | First-episode schizophrenia | Normal controls matched for age, sex, SES | 42 (16/38) | 11 (3/27) | 0.007 | |
2002 | Boronow et al. (31) United States | EIA | Outpatients with schizophrenia | Normal controls matched for age | 12 (28/229) | 7 (7/100) | 0.147 | |
2003 | Leweke et al. (32) Germany | EIA | First-episode schizophrenia, never treated | Normal controls matched for age, sex, SES | 36 (13/36) | 14 (10/73) | <0.007 | |
2003 | Torrey & Yolken (unpub. data) Ireland | EIA | Inpatients with schizophrenia | Hospital employees | 60 (31/52) | 45 (9/20) | 0.299 |
C.F., complement fixation; EIA, enzyme immunoassay; Ig, immunoglobulin; SES, socioeconomic status.
Page created: January 21, 2011
Page updated: January 21, 2011
Page reviewed: January 21, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.